Endomimetics® is a biomedical innovation IP Foundry that provides healing solutions to improve the performance and safety profiles of surgical and implantable products. Our proprietary Bionanomatrix™ technology, which powers our peptide-based coating and gel formulations, significantly boosts the safety and efficacy of medical procedures. With leading products such as the Vascular Access Gel, we're dedicated to reducing medical complications and transforming the quality of life for current and future generations.
Platform level upside, Application level clarity
Endomimetics is building a scalable Bionanomatrix™ platform while structuring each major application as a standalone, indication focused company, giving investors both diversified platform exposure and the option to back single asset stories with clear milestones and exits.
Compounding value from retained IP and economics
The parent company, Endomimetics, owns all core IP and patents and captures value from each spinout through upfront payments, milestones, royalties, and equity stakes, creating a portfolio of assets whose value compounds as additional new companies are launched and de-risked.
Disciplined focus on high value, de-risked indications
Research and development efforts are concentrated only where Bionanomatrix delivers a clear scientific and clinical edge, with internal work generating robust preclinical and early clinical data so each asset is “transaction ready” for dedicated capitalization and strategic interest.
Aligned financing pathways for different investor profiles
Platform level capital supports ongoing IP, discovery, and pipeline creation for investors seeking diversified optionality, while each new company offers a focused, indication specific vehicle with defined timelines, value inflections, and exit routes.
Execution leverage with a lean core and specialist teams
Endomimetics stays lean and R&D centric, while each spinout will be lead by its own experienced management team to drive clinical development, regulatory approval strategy, business development, and M&A in its target segment—improving execution quality without complicating the R&D efforts at Endomimetics.
Multiple, repeatable exit opportunities
The model is engineered as an “IP Foundry”: spinouts are cleanly acquirable or licensable once key inflection points are reached, and, as more programs mature, the parent company’s portfolio of equity and licenses becomes itself an attractive acquisition or financial sponsor target.
Endomimetics® has raised over $10 million to date, validating both the Bionanomatrix™ platform and its centralized accelerator model for systematically generating de‑risked applications.
The current $3–5 million raise is aimed at the platform level, funding core IP, discovery, and early R&D to advance lead programs (such as the Vascular Access Gel and aneurysm coatings) to clear, “spinout‑ready” inflection points.
At the application level, each major Bionanomatrix™ application will be capitalized in its own focused company with an exclusive, field‑specific license, creating clean, acquirable vehicles in high‑value markets like vascular access and aneurysm treatment.
Investors participating now gain leveraged exposure to both tiers of value creation: diversified, compounding upside from Endomimetics’ portfolio of licenses and equity stakes, and future opportunities to invest directly into single‑asset newcos as they are formed and scaled.
Current applications of the Bionanomatrix™ under development are projected to have a total addressable market of $37.9 billion by 2032 and a potential technology footprint in the USA, European Union, and Rest of the World.
Explore the latest updates on our research, product developments, and partnerships. Additionally, get access to expert insights in the field of bioengineering.
